| 30/08/2019 |
Appendix 4E |
| 19/12/2017 |
Cleansing Statement and Appendix 3B |
| 15/12/2017 |
Cellmid Placement to Strategic Investor |
| 07/12/2017 |
Cellmid Secures New US Retail Partner for évolis® |
| 05/12/2017 |
Cellmid Capital Structure Post Consolidation |
| 28/11/2017 |
YPB and Cellmid Sign Agreement to Access Chinese Consumer Health Market |
| 24/11/2017 |
Change of Auditor |
| 23/11/2017 |
AGM Presentation to Shareholders |
| 23/11/2017 |
Results of Annual General Meeting |
| 23/11/2017 |
Update – Consolidation split/CDY |
| 16/11/2017 |
Appendix 3B – Unlisted Options |
| 15/11/2017 |
Appendix 3E and 3F |
| 15/11/2017 |
ASIC Form 484 |
| 01/11/2017 |
Change of Director’s Interest Notice – Cross |
| 01/11/2017 |
Change of Director’s Interest notice – Walton |
| 31/10/2017 |
Cellmid presents at world congress for hair research |
| 31/10/2017 |
Change of Director’s Interest Notice – King |
| 26/10/2017 |
Cellmid opens first concept store in Tokyo |
| 25/10/2017 |
Announcement of buy-back – Appendix 3C |
| 25/10/2017 |
Appendix 4C – quarterly |
| 24/10/2017 |
Proposed Consolidation of Securities |
| 23/10/2017 |
Cellmid Annual Report to Shareholders |
| 23/10/2017 |
Consolidation/split – CDY |
| 23/10/2017 |
Notice of Annual General Meeting/Proxy form |
| 16/10/2017 |
Cellmid Appoints Dr Martin Cross as Non-Executive Director |
| 12/10/2017 |
Date of Annual General Meeting |
| 03/10/2017 |
Cellmid Receives $947K R&D Tax Credit |
| 03/10/2017 |
Cellmid to Present at Proactive Investors Event |
| 27/09/2017 |
2017 FY Results Investor Presentation |
| 25/09/2017 |
Change of Share Registry Details |
| 21/08/2017 |
Cellmid Completes US Consumer Study |
| 03/08/2017 |
Cellmid Secures US Premium Retail for evolis |
| 01/08/2017 |
Cellmid Receives Chinese Import Permits |
| 28/07/2017 |
Notes to Appendix 4C |
| 03/07/2017 |
Nature Paper: MK in Melanoma |
| 19/04/2017 |
Notes to Appendix 4C |
| 02/03/2017 |
Cellmids FGF5 Inhibitor Clinical Study Published |
| 01/03/2017 |
Cellmid to Refinance R&D Loan Facility |
| 28/02/2017 |
Appendix 4D and Half Year Accounts |
| 07/02/2017 |
European Midkine Alopecia Patent Allowed |
| 31/01/2017 |
USA Midkine Alopecia Patent Allowed |
| 24/01/2017 |
Notes to Appendix 4C |
| 18/01/2017 |
Cellmid Receives Australian Government Grant For Midkine Programme |
| 18/01/2017 |
Change of Director’s Interest Notice – Maria Halasz |
